Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2002

View Archived Issues

Cytokinetics describes preparation and use of mitotic kinesin KSP inhibitors

Bupropion hydrochloride safe, promotes smoking cessation among smokers

Roflumilast safe and effective in patients with asthma and COPD

Adding montelukast as effective as doubling budesonide dose in asthma patients

Columbia reports progress on development products

Two rhBMP-2-based products now cleared for marketing

Gene-based company to result from Vascular Genetics/GenStar Therapeutics merger

ODAC votes for accelerated approval of Iressa

Clinical trials of potential oral therapy for COPD suspended by Ono

New 5-HT2A/5-HT2C modulators for use in obesity, schizophrenia and depression

New LFA-1 antagonists identified at Genentech

Pharmacia claims new antibacterial oxazolidinones in recent patent

Androgenic agents discovered at Schering AG

Indolinones disrupt the function of wild-type and mutant Kit

HHS patents new antiretroviral series

Selective hypoxic radiosensitizing effects of PR-350 examined in pancreatic cancer cell lines

Functional fatty acid compound tested in patients with NASH in U.S. trial

Inclusion of superiority data in Atacand labeling approved

ETC-642 evaluated in second phase I trial

Tracvax protects against Chlamydia infection in preclinical studies

Interim phase II results for TOCOSOL(TM) Paclitaxel

RSR-13 improves median survival in NSCLC

TNX-901 for peanut allergy receives fast track status

New trial for Genasense plus thalidomide in multiple myeloma

Phenoxodiol enters phase II leukemia trial

Phase II trial evaluates Paxceed in RA

Patient enrollment completed in phase IIb renzapride trial in IBS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...